Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma.
Sumanta Kumar PalDavid F McDermottMichael B AtkinsBernard EscudierBrian I RiniRobert J MotzerLawrence FongRichard W JosephStephane OudardAlain RavaudSergio BracardaCristina SuárezElaine T LamToni K ChoueiriBeiying DingCaroleen QuachKenji HashimotoChristina SchiffElisabeth Piault-LouisThomas PowlesPublished in: BJU international (2020)
PROs suggested that atezolizumab alone or with bevacizumab maintained daily function compared with sunitinib. Notably, symptoms were least severe with atezolizumab alone vs sunitinib (IMmotion150; ClinicalTrials.gov Identifier: NCT01984242).